ライフサイエンスコーパス: peripheral vascular disease

1 cerebrovascular disease, heart failure, and peripheral vascular disease).

2 heart disease, congestive heart failure, or peripheral vascular disease).

3 ain (ischemic stroke), or lower extremities (peripheral vascular disease).

4 included a history of diabetes, smoking, and peripheral vascular disease.

5 fested as myocardial infarction, stroke, and peripheral vascular disease.

6 tion distinct from patients with coronary or peripheral vascular disease.

7 uated as a gene therapy for the treatment of peripheral vascular disease.

8 r cardiovascular endpoints such as stroke or peripheral vascular disease.

9 raphy in patients known or suspected to have peripheral vascular disease.

10 VEGF-induced angiogenesis as well as severe peripheral vascular disease.

11 nsient ischemic attack, and new diagnosis of peripheral vascular disease.

12 One subject also had premature coronary and peripheral vascular disease.

13 and in the treatment of coronary artery and peripheral vascular disease.

14 tion, diabetes, hypertension, and history of peripheral vascular disease.

15 s in women, older patients and patients with peripheral vascular disease.

16 sing prevalence and associated complexity of peripheral vascular disease.

17 aphic follow-up of patients with coronary or peripheral vascular disease.

18 3 mg/dl, and the patient has no worsening of peripheral vascular disease.

19 tive heart failure, renal insufficiency, and peripheral vascular disease.

20 contrast volume and ionicity, and extent of peripheral vascular disease.

21 agement of patients with coronary artery and peripheral vascular disease.

22 sociated with coronary heart disease but not peripheral vascular disease.

23 ot associated with coronary heart disease or peripheral vascular disease.

24 derwent MR angiography for the evaluation of peripheral vascular disease.

25 ept in conjunction with renal dysfunction or peripheral vascular disease.

26 ial infarction, congestive heart failure, or peripheral vascular disease.

27 monary disease, diabetes, heart failure, and peripheral vascular disease.

28 type 2 diabetes, heart disease, stroke, and peripheral vascular disease.

29 ties to achieve health equity for women with peripheral vascular disease.

30 ion, heart failure, atrial fibrillation, and peripheral vascular disease.

31 ated with amputation, including diabetes and peripheral vascular disease.

32 luenced graft failure censored for death was peripheral vascular disease.

33 nt and effective management of patients with peripheral vascular disease.

34 ythmias, stroke, venous thromboembolism, and peripheral vascular disease.

35 , cardiac arrest, chronic heart disease, and peripheral vascular disease.

36 s should be considered for all patients with peripheral vascular disease.

37 tor for ischemic heart, cerebrovascular, and peripheral vascular disease.

38 ary calcium, coronary revascularization, and peripheral vascular disease.

39 r severe calcification, and in patients with peripheral vascular disease.

40 s in the OZR, a model of non-atherosclerotic peripheral vascular disease.

41 esentation of coronary, cerebrovascular, and peripheral vascular diseases.

42 mer's disease, vascular dementia, heart, and peripheral vascular diseases.

43 0.0001), diabetes (0.62, 0.43-0.90; p=0.01), peripheral vascular disease (0.27, 0.17-0.45; p<0.0001),

44 istory of malignancy (1.44 [1.03-2.09]), and peripheral vascular disease (1.33 [1.04-1.70]).

45 69), peptic ulcer disease (1.27; 1.03-1.58), peripheral vascular disease (1.38; 1.07-1.77), renal dis

46 mm Hg), 1.86 for diabetes mellitus, 1.83 for peripheral vascular disease, 1.79 for smoking (>20 cigar

47 renal failure, and heart failure; 0.591 for peripheral vascular disease; 1.599 for cerebrovascular d

48 17/1,000 years, p < 0.001), and symptomatic peripheral vascular disease (10.6 vs. 3.5/1,000 years, p

49 %, female gender 28%, diabetes mellitus 27%, peripheral vascular disease 11%, cerebrovascular disease

50 iovascular disease (38%), diabetes (26%) and peripheral vascular disease (14.5%).

51 etes mellitus (37.1%), hypertension (80.5%), peripheral vascular disease (15.3%), and renal disease (

52 hypertension (40.7% versus 47.9%; P<0.001), peripheral vascular disease (2.4% versus 3.3%; P=0.002),

53 (relative risk 2.79 [95% CI 1.28-6.93]) and peripheral vascular disease (2.83 [1.29-6.17]), but not

54 yocardial infarction, pulmonary embolism and peripheral vascular disease(2-4) by removing clots throu

55 duced kidney function (31% vs. 24%), and had peripheral vascular disease (21% vs. 11%) more often tha

56 betes with chronic complication (37.3%), and peripheral vascular disease (30.4%).

57 t per hospital discharge was the highest for peripheral vascular disease ($33 700 [95% CI, $33 300-$3

58 tery bypass graft surgery (19.8% vs. 61.2%), peripheral vascular disease (36.4% vs. 46.9%), diabetes

59 %), infections (12.8%), bleeding (7.6%), and peripheral vascular disease (4.3%) were the most common

60 dicted by posttransplant cerebral (8.25) and peripheral vascular disease (4.58).

61 s strongly predictive of cerebral (5.80) and peripheral vascular disease (5.22), whereas ischemic hea

62 re hypertension (63% vs. 55%, respectively), peripheral vascular disease (8.2% vs. 5.2%, respectively

63 216.9; -12%, 95% CI -17 to -6; p=0.0003) and peripheral vascular disease (97.9 vs 86.5; -12%, -21 to

64 rs and 84 patients with clinically suspected peripheral vascular disease, a stepping kinematic imagin

65 ior stroke, prior transient ischemic attack, peripheral vascular disease, absence of prior coronary a

66 ates of amputation and revascularization for peripheral vascular disease across race/ethnicity.

67 -duration sleeper were higher among men with peripheral vascular disease (adjusted odds ratio (aOR) =

68 nsion, diabetes, ischaemic heart disease and peripheral vascular disease (adjusted OR=1.4, 2.0, 1.9 a

69 Peripheral vascular disease affects millions of individu

70 rs for ischemic heart disease, cerebral, and peripheral vascular disease after 706 renal transplants,

71 ngiography for evaluation of lower extremity peripheral vascular disease after conventional digital s

72 Heart Failure Model, the PACE (incorporating peripheral vascular disease, age, creatinine, and ejecti

73 valvular heart disease (aHR, 1.221.321.43), peripheral vascular disease (aHR, 1.051.181.33), chronic

74 heart failure (HF), atrial fibrillation, and peripheral vascular disease, all of which were associate

75 more between arms have been associated with peripheral vascular disease and attributed to subclavian

76 its of LDL cholesterol reduction extend into peripheral vascular disease and cerebrovascular disease

77 wounds resulting from comorbidities, such as peripheral vascular disease and diabetes mellitus, tend

78 betes are uniquely susceptible to developing peripheral vascular disease and fill important gaps in o

79 men and white and with a lower prevalence of peripheral vascular disease and history of prior cardiac

80 Peripheral vascular disease and IADL impairment, but not

81 the number of previous TCVC, the presence of peripheral vascular disease and indication were independ

82 ee categories: no diabetes, diabetes without peripheral vascular disease and renal failure, and diabe

83 atly affected by associated comorbidities of peripheral vascular disease and renal failure.

84 c syndrome is an independent risk factor for peripheral vascular disease and thrombotic events within

85 of sex-based differences and disparities in peripheral vascular disease and to provide research prio

86 eart rate reserve, a pattern consistent with peripheral vascular disease and/or a myopathy.

87 disease and renal failure, and diabetes with peripheral vascular disease and/or renal failure.

88 litate the early detection and monitoring of peripheral vascular diseases and may be advantageous for

89 he primary cause of coronary artery disease, peripheral vascular disease, and a large proportion of s

90 esterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases.

91 logistic regression, CAC, ECG R-R variation, peripheral vascular disease, and Beck Depression Invento

92 eters (TCVC) prior to insertion of an ecAVG, peripheral vascular disease, and BMI were significant as

93 disease, cerebral infarction, heart failure, peripheral vascular disease, and cardiac arrhythmia) and

94 ropathy, retinopathy, peripheral neuropathy, peripheral vascular disease, and cardiovascular disease.

95 were coronary artery disease, graft failure, peripheral vascular disease, and cause of end-stage rena

96 gher prevalence of coronary atherosclerosis, peripheral vascular disease, and cerebrovascular calcifi

97 isk of myocardial infarction, heart failure, peripheral vascular disease, and cerebrovascular disease

98 ASCVD was defined as coronary heart disease, peripheral vascular disease, and cerebrovascular disease

99 e indication, bipolar depression, age group, peripheral vascular disease, and cognitive performance.

100 on and other coronary heart disease, stroke, peripheral vascular disease, and congestive heart failur

101 (heart attack and angina pectoris), stroke, peripheral vascular disease, and diabetes, 81.7% (140 mi

102 it (such as coronary heart disease, stroke, peripheral vascular disease, and heart failure) over a f

103 and nonfatal coronary heart disease, stroke, peripheral vascular disease, and heart failure).

104 nary heart disease, cerebrovascular disease, peripheral vascular disease, and heart failure.

105 Hispanic ethnicity, cerebrovascular disease, peripheral vascular disease, and ischemic heart disease

106 splantation comorbidities (diabetes, angina, peripheral vascular disease, and MI), transplantation fr

107 om any cause, myocardial infarction, stroke, peripheral vascular disease, and microvascular disease)

108 xists between this difference and central or peripheral vascular disease, and mortality.

109 Heart failure, renal failure, liver disease, peripheral vascular disease, and non-atrial fibrillation

110 infarction, cerebrovascular disease, sepsis, peripheral vascular disease, and organ transplantation.

111 Patients with diabetes, cardiac disease, peripheral vascular disease, and poor functional status

112 k factor for stroke, ischemic heart disease, peripheral vascular disease, and progressive renal damag

113 years, 55.4% were male, 7.6% of patients had peripheral vascular disease, and the mean Society of Tho

114 years, 55.4% were male, 7.6% of patients had peripheral vascular disease, and the mean Society of Tho

115 ry atherosclerosis, cerebrovascular disease, peripheral vascular disease, and thrombosis.

116 portal hypertension, ischemic heart disease, peripheral vascular disease, and tumor angiogenesis.

117 ibrillation, heart failure, thromboembolism, peripheral vascular disease, and type 2 diabetes.

118 ervention, prior myocardial infarction (MI), peripheral vascular disease, and ulcerated lesion (P<0.0

119 ug-coated balloons are increasingly used for peripheral vascular disease, and, yet, mechanisms of tis

120 farction, ischemic heart disease, stroke, or peripheral vascular disease; and had greater baseline se

121 er income; dementia; chronic kidney disease; peripheral vascular disease; and, among patients aged 65

122 e, hypertension, chronic kidney disease, and peripheral vascular disease; and, among those aged 66 ye

123 ed renal failure (aOR = 7.49, p = 0.01), and peripheral vascular disease (aOR = 6.92, p = 0.01), whic

124 ion (aOR, 1.26; 95% CI, 1.03-1.54; P = .03), peripheral vascular disease (aOR, 1.24; 95% CI, 1.02-1.4

125 .44 in network 17 versus 1.00 in network 1), peripheral vascular disease (AOR, 1.65), black race (AOR

126 enges, which include acute aortic syndromes, peripheral vascular disease, aortic stent-graft and tran

127 Patients who require surgical treatment of peripheral vascular disease are at increased risk of per

128 Data on sex differences in peripheral vascular disease are ill defined, and there i

129 lar disorders, stroke, rhythm disorders, and peripheral vascular disease are reviewed.

130 gic stroke (HR=2.16, 95% CI: 1.68-2.77), and peripheral vascular disease/arteriosclerosis (HR=2.05, 9

131 athogenesis of cerebrovascular, coronary and peripheral vascular disease as well as corneal opacifica

132 oke, heart failure, atrial fibrillation, and peripheral vascular disease), as well as pulmonary embol

133 troke, carotid disease, aortic aneurysm, and peripheral vascular disease), as well as those individua

134 ath from any cause, but a risk reduction for peripheral vascular disease associated with tight blood-

135 he rate of cognitive decline associated with peripheral vascular disease, atherosclerosis of the comm

136 gistic regression analysis identified shock, peripheral vascular disease, balloon angioplasty strateg

137 egaly any time before discharge, presence of peripheral vascular disease, body mass index <20 kg/m2,

138 factors are very prevalent in patients with peripheral vascular disease, but these patients receive

139 Selected patients with peripheral vascular disease can be treated with spinal c

140 tive heart failure, cerebrovascular disease, peripheral vascular disease, cardiac arrhythmias and the

141 telehealth utilization on cardiovascular and peripheral vascular disease care, and identifies obstacl

142 enal failure (serum creatinine = 2.5 mg/dL), peripheral vascular disease, cerebrovascular accident, a

143 een arms, with data for subclavian stenosis, peripheral vascular disease, cerebrovascular disease, ca

144 ellitus, as well as comorbidities, including peripheral vascular disease, cerebrovascular disease, ch

145 eep apnea, diabetes mellitus, heart failure, peripheral vascular disease, chronic kidney disease, chr

146 ties (coronary heart disease, heart failure, peripheral vascular disease, chronic lung disease, diabe

147 95% CIs adjusted for diabetes, hypertension, peripheral vascular disease, chronic obstructive pulmona

148 nge in the prevalence of cerebrovascular and peripheral vascular disease, chronic obstructive pulmona

149 r dysfunction, increasing age, cardiomegaly, peripheral vascular disease, chronic renal insufficiency

150 ding Stents Placed in Legs of Diabetics With Peripheral Vascular Disease [COBRA]; NCT00827853).

151 ence of bicuspid aortic valve, diabetes, and peripheral vascular disease compared with the OUS cohort

152 ut for angina, congestive heart failure, and peripheral vascular disease, concordance was only fair t

153 eral comorbidities (cerebrovascular disease, peripheral vascular disease, congestive heart failure, c

154 increased serum creatinine, presence of RAS, peripheral vascular disease, congestive heart failure, d

155 utcomes included lower extremity amputation, peripheral vascular disease, critical limb ischemia, ost

156 ovascular disease, cerebrovascular accident, peripheral vascular disease, diabetes mellitus, liver di

157 nary bypass, acute cerebrovascular ischemia, peripheral vascular disease, diabetes mellitus, preeclam

158 ultivariable regression analysis, older age, peripheral vascular disease, diabetes, and time on dialy

159 2,000, prior CABG, congestive heart failure, peripheral vascular disease, diabetes, hypertension, and

160 isease, ischemic heart, cerebrovascular, and peripheral vascular disease; diabetes; autoimmune thyroi

161 diabetes, dyslipidemia, smoking, cerebral or peripheral vascular disease, etc.) contributing to incre

162 The incidence of cerebrovascular events and peripheral vascular disease events is similar in patient

163 Peripheral vascular disease existed in 308 KT candidates

164 ce of 10 mm Hg or higher was associated with peripheral vascular disease (five studies; RR 2.4, 1.5-3

165 below knee amputation from 14 patients with peripheral vascular disease following quantification of

166 iminate the excess of cardiac, cerebral, and peripheral vascular diseases found in diabetic patients.

167 , chronic obstructive pulmonary disease, and peripheral vascular disease had greater prognostic signi

168 The development of cell therapies to treat peripheral vascular disease has proven difficult because

169 without the sequelae of renal failure and/or peripheral vascular disease have long-term survival simi

170 For DDKT recipients, peripheral vascular disease (hazard ratio [HR] 3.04, 95%

171 rial fibrillation (2.84; 95% CI, 1.46-5.53), peripheral vascular disease (hazard ratio, 2.02; 95% CI,

172 Diabetes was associated with hypertension, peripheral vascular disease, history of stroke, clinical

173 (HR 1.41), myocardial infarction (HR 1.34), peripheral vascular disease (HR 1.27), and revasculariza

174 2.90), stroke (HR 1.71, 95% CI 1.34, 2.17), peripheral vascular disease (HR 1.80, 95% CI 1.44, 2.27)

175 7% lower risk of a hospitalization for other peripheral vascular disease (HR: 0.53; 95% CI: 0.42, 0.6

176 8; 95% confidence interval [CI], 1.39-1.80), peripheral vascular disease (HR=1.41; 95% CI, 1.11-1.80)

177 cer hospitalizations, insulin treatment, and peripheral vascular disease; HR=1.19, 95% CI=1.04-1.36,

178 (deep venous thrombosis/pulmonary embolism, peripheral vascular disease, hypercoagulable state, myoc

179 ary heart disease in diabetic women and with peripheral vascular disease in both sexes.

180 flow as a critical factor due to the role of peripheral vascular disease in DFU development.

181 be clinically valuable in situations such as peripheral vascular disease in diabetic patients and tis

182 eiving a second transplant and (2) reporting peripheral vascular disease in kidney transplantation to

183 A heightened awareness of coexisting peripheral vascular disease in patients transplanted for

184 eatment strategy for patients with extensive peripheral vascular disease in whom the use of intravasc

185 ncidence of 12 cardiac, cerebrovascular, and peripheral vascular diseases in women and men at differe

186 c events (myocardial infarction, stroke, and peripheral vascular disease) in a prospective cohort of

187 Although peripheral vascular disease is a highly diverse group of

188 Peripheral vascular disease is a manifestation of system

189 Peripheral vascular disease is a strong predictor of mor

190 Percutaneous therapy for peripheral vascular disease is associated with minimal m

191 d balloon (DCB) therapy for the treatment of peripheral vascular disease is that it allows for reopen

192 Whether this also holds for a spectrum of peripheral vascular diseases is unknown.

193 ischemic conditions such as severe end-stage peripheral vascular disease, ischemic heart disease and

194 VD comprising stroke, myocardial infarction, peripheral vascular disease, ischemic heart disease, and

195 a major risk factor for coronary artery and peripheral vascular diseases, its role in the pathogenes

196 ystematic review of studies published in top peripheral vascular disease journals to determine what t

197 vs. 16.95; p < 0.001), with a higher rate of peripheral vascular disease, known coronary artery disea

198 infarction, 0.56 (95% CI, 0.40 to 0.80); for peripheral vascular disease leading to amputation, 0.57

199 h, fatal and nonfatal myocardial infarction, peripheral vascular disease leading to amputation, and f

200 ge, diabetes mellitus, chronic lung disease, peripheral vascular disease, left main trunk stenosis, a

201 , diabetes mellitus, stroke, upper leg pain, peripheral vascular disease, left ventricular hypertroph

202 renal insufficiency, low ejection fraction, peripheral vascular disease, lesion characteristics, fem

203 Secondary outcomes were MACE or peripheral vascular disease (MACE-PVD), and all-cause mo

204 cardiogenic shock, renal disease, history of peripheral vascular disease, multivessel disease, widowh

205 ischemic heart disease, cerebrovascular, and peripheral vascular disease), musculoskeletal disorders,

206 = 69 (17.8 %)), stroke (n = 62 (16.0 %)) and peripheral vascular disease (n = 49 (12.7 %)).

207 ypertension; intermediate (0.40 to 0.52) for peripheral vascular disease, neoplasm, myocardial infarc

208 farction, aortic stenosis, female sex, race, peripheral vascular disease, New York Heart Association

209 ence of 15 mm Hg or more was associated with peripheral vascular disease (nine cohorts; RR 2.5, 95% C

210 nsion, age 75 years, valvular heart disease, peripheral vascular disease, obesity, congestive heart f

211 lly to image hypoxic tissue in solid tumors, peripheral vascular disease of diabetic origin, blunt br

212 idence of CVD (coronary, cerebrovascular, or peripheral vascular disease or heart failure) during 10

213 lmonary bypass time >120 minutes (OR = 6.2), peripheral vascular disease (OR = 2.2), renal (OR = 3.2)

214 1-2 units, OR, 1.47 [0.98-2.22]) followed by peripheral vascular disease (OR, 1.48 [1.05-2.10]), hist

215 P = .0073), no history of cerebrovascular or peripheral vascular disease (OR, 3.13; P = .0071), recei

216 ed ileus were male sex (OR: 1.7, P < 0.001), peripheral vascular disease (OR: 1.8, P < 0.001), respir

217 1.20; 95% CL: 1.08 to 1.34), and underlying peripheral vascular disease (OR: 4.86; 95% CL: 1.66 to 1

218 5% confidence interval [95% CI] 1.13, 2.82), peripheral vascular diseases (OR 2.21, 95% CI 1.37, 3.60

219 te for diabetic subjects with renal failure, peripheral vascular disease, or both was 9.4 deaths per

220 sk for myocardial infarction, heart failure, peripheral vascular disease, or cerebrovascular disease

221 e likely to be female; to have hypertension, peripheral vascular disease, or cerebrovascular disease;

222 reduced left ventricular ejection fraction, peripheral vascular disease, or chronic obstructive pulm

223 allele in combination with atherosclerosis, peripheral vascular disease, or diabetes mellitus were a

224 any coronary event, a cerebrovascular event, peripheral vascular disease, or heart failure), death, m

225 nary heart disease, cerebrovascular disease, peripheral vascular disease, or heart failure).

226 in patients without coronary artery disease, peripheral vascular disease, or ischemic stroke were eva

227 tion, chronic obstructive pulmonary disease, peripheral vascular disease, or renal disease.

228 osclerotic disease (coronary artery disease, peripheral vascular disease, or stroke).

229 rted range for CRP as a risk factor for CVD, peripheral vascular diseases, or stroke is 1.34 mg/l to

230 .21 for cerebral vascular disease, and 28.18 peripheral vascular disease (P < 0.05).

231 us as the primary cause of ESRD (P = 0.002), peripheral vascular disease (P = 0.004), white race (P =

232 A larger proportion of males suffered from peripheral vascular disease (P = 0.02) and ischemic hear

233 Risks factors for Group 1 included peripheral vascular disease (P<0.0001) and cerebrovascul

234 vascular disease (P=0.04), CHF (P=0.02), and peripheral vascular disease (P=0.03).

235 vidence of chronic disease, including severe peripheral vascular disease, patchy cardiac fibrosis, an

236 hildhood body mass index and higher rates of peripheral vascular disease (per each 1-standard deviati

237 cade have broadened the options for treating peripheral vascular disease percutaneously.

238 ated health, high cholesterol, hypertension, peripheral vascular disease, physical activity, smoking,

239 Bleeding event, peak troponin T level, and peripheral vascular disease predict mortality within 30

240 me were pretransplant smoking, pretransplant peripheral vascular disease, pretransplant dialysis for

241 Peripheral vascular disease prevalence more than doubled

242 od pressure, history of diabetes mellitus or peripheral vascular disease, primary renal disease class

243 a; previous coronary artery bypass grafting; peripheral vascular disease; procedure- and lesion-relat

244 brillation PRS (OR = 1.12, 95%CI 1.03-1.22), peripheral vascular disease PRS (OR = 0.9, 95%CI 0.82-0.

245 Risk of myocardial infarction, stroke, peripheral vascular disease, pulmonary embolism, hyperte

246 to 3.24, p = 0.02) for in-hospital MACE, and peripheral vascular disease (PVD) (OR: 2.18, CI: 1.34 to

247 oncern for medical practitioners in treating Peripheral Vascular Disease (PVD) and Coronary Artery Di

248 The association between peripheral vascular disease (PVD) and survival among kid

249 ze renal allograft outcomes in patients with peripheral vascular disease (PVD) at the time of transpl

250 profound increase in risk for development of peripheral vascular disease (PVD) in afflicted persons.

251 Peripheral vascular disease (PVD) is an atherosclerotic

252 Peripheral vascular disease (PVD) is common among patien

253 Peripheral vascular disease (PVD) is highly prevalent in

254 Psoriasis, venous thromboembolism (VTE), and peripheral vascular disease (PVD) share similar mechanis

255 ase (CAD), angina, heart attack, stroke, and peripheral vascular disease (PVD) were determined.

256 rrest), ASCVD (CHD and ischemic stroke), and peripheral vascular disease (PVD) were evaluated separat

257 line demographics and comorbidities, such as peripheral vascular disease (PVD), diabetes, ischemic he

258 sease (CHD), diabetes, hearing difficulties, peripheral vascular disease (PVD), respiratory difficult

259 th COVID-19 adjusted according to history of peripheral vascular disease (PVD).

260 y (PTCA) may be different in the presence of peripheral vascular disease (PVD).

261 dous advances have occurred in therapies for peripheral vascular disease (PVD); until recently, howev

262 ts (6 healthy volunteers and 2 patients with peripheral vascular disease [PVD]) were injected with a

263 Adults known or suspected to have peripheral vascular disease received gadofosveset (0.03

264 nt, longer dialysis duration, more diabetes, peripheral vascular disease, reduced functional status,

265 tial TEVAR was associated with hypertension, peripheral vascular disease, region, Medicaid dual eligi

266 tive heart failure, cerebrovascular disease, peripheral vascular disease, renal disease, and liver di

267 vascular disease, neurodegenerative disease, peripheral vascular disease, renal disease, and several

268 issues can lead to myocardial infarction and peripheral vascular disease, respectively.

269 coronary artery disease, cerebral ischemia, peripheral vascular disease, restenosis, and tissue edem

270 iac) was the chief cause of mortality, while peripheral vascular disease resulted in several amputati

271 ial infarction, renal insufficiency/failure, peripheral vascular disease, retinopathy, dementia, and

272 e and rheumatic diseases (RR 1.5 [1.3-1.7]), peripheral vascular disease (RR 1.4 [1.1-1.7]), surgery

273 oke (RR, 0.42; 95% CI, 0.26-0.69; P < .001), peripheral vascular disease (RR, 0.47; 95% CI, 0.28-0.79

274 injury, such as atherosclerosis, restenosis, peripheral vascular disease, sepsis, and acute respirato

275 antify microvascular changes associated with peripheral vascular disease, skin inflammation and rheum

276 nary syndrome, new-onset angina, symptomatic peripheral vascular disease, stroke, and transient ische

277 opathy, neuropathy, cardiovascular diseases, peripheral vascular diseases, stroke, and periodontal pa

278 the recommended Doppler-aided assessment for peripheral vascular disease than patients living in the

279 heart failure, azotemia, bypass surgery, and peripheral vascular disease than patients with ST-elevat

280 greater risk of skin and bladder cancers and peripheral vascular disease, these results suggest that

281 d the risk of coronary, cerebrovascular, and peripheral vascular diseases to a similar extent.

282 hours, shock, congestive heart failure, and peripheral vascular disease), to predict in-hospital mor

283 al infarction, cardiac failure, diabetes and peripheral vascular disease, transient ischaemic attack

284 women aged 56-79 years) suspected of having peripheral vascular disease underwent multistation whole

285 +/- 14), who were referred for evaluation of peripheral vascular disease, underwent peripheral contra

286 teries using ultrasonography; measurement of peripheral vascular disease using ankle and brachial blo

287 edures and deaths in the 2 treatment groups; peripheral vascular disease was a predefined secondary o

288 tcomes (ischemic cerebrovascular disease and peripheral vascular disease), we found independent assoc

289 ential clinical utility of this approach for peripheral vascular disease, we investigated the ability

290 meter, moderate or severe calcification, and peripheral vascular disease were associated with higher

291 MR angiographic results in two patients with peripheral vascular disease were compared with their res

292 Female gender, high age and peripheral vascular disease were independent predictors

293 eline characteristics, although diabetes and peripheral vascular disease were more common in the usua

294 ions during or after the trial for stroke or peripheral vascular disease were observed for both inten

295 he case of a diabetic patient with extensive peripheral vascular disease who, after 7 years on hemodi

296 w in patients with severe ischemic heart and peripheral vascular disease, who are not candidates for

297 ction, congestive heart failure, stroke, and peripheral vascular disease with adjusted risk ratios of